Barclays Maintains Overweight Rating for Intellia Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Barclays has maintained its Overweight rating for Intellia Therapeutics (NASDAQ:NTLA) and increased its price target from $86.00 to $90.00. Despite the shares trading down 0.78% over the last 24 hours, the new price target represents a 129.01% increase from the current share price. Intellia Therapeutics is a gene editing company that uses CRISPR/Cas9-based therapeutics to treat genetically defined diseases.
August 07, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has maintained its Overweight rating for Intellia Therapeutics and increased its price target, indicating a positive outlook for the company.
The maintenance of the Overweight rating and the increase in price target by Barclays indicates a positive outlook for Intellia Therapeutics. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100